Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

initiative

- PMLiVE

HRW Wins 2026 Artificial Intelligence Excellence Award in the Pharmaceutical Category

Healthcare Research Worldwide (HRW) has been named a winner in the 2026 Artificial Intelligence Excellence Awards in the Pharmaceutical category, recognizing its innovative use of AI to deliver real-world impact....

Healthcare Research Worldwide

- PMLiVE

J&J’s nipocalimab gets FDA Fast Track designation for lupus

The autoimmune disease affects approximately three to five million people globally

- PMLiVE

Johnson & Johnson’s Darzalex Faspro regimen receives FDA approval for multiple myeloma

Multiple myeloma has an average five-year survival rate of 59.8% and is currently incurable

- PMLiVE

Johnson & Johnson’s Rybrevant shows positive effects in difficult-to-treat colorectal cancer

Colorectal cancer accounts for around 10% of all cancer cases globally, with an increase in diagnoses in younger people

- PMLiVE

J&J receives positive NICE recommendation for multiple myeloma treatment

The treatment is approved for use within the NHS in England and Wales

- PMLiVE

Johnson & Jonson secures FDA approval for multiple myeloma treatment

Support for first and only high-risk smouldering multiple myeloma treatment came from positive phase 3 trial results

- PMLiVE

Innovation in Action at AAFP FMX 2025

This year, Medscape Education is redefining the live learning experience at AAFP FMX 2025. With 8 groundbreaking, accredited symposia, we are proud to be at the heart of the meeting,...

Medscape Education

- PMLiVE

Breakthrough Alzheimer’s Therapies Drive Early Detection Rates While Exposing Deep Treatment Disparities

Analysis from Komodo Health and Medscape Education shows cognitive screening up 10% and biomarker testing up 23%, yet significant disparities persist in detection for women and treatment access for Black...

Medscape Education

- PMLiVE

Johnson & Johnson seeks first EMA approval for icotrokinra for plaque psoriasis

Icotrokinra is a first-in-class, once-daily tablet for moderate-to-severe plaque psoriasis

- PMLiVE

John Morikis joins Johnson & Johnson’s board of directors

Morikis was previously Chairman, President and CEO at Sherwin-Williams

- PMLiVE

Medscape Cardiology: Leading the Future of Heart Failure Education at HFSA 2025

Medscape Cardiology | theheart.org is proud to be at the forefront of the Heart Failure Society of America (HFSA) Annual Scientific Meeting (ASM), September 26–29, 2025, in Minneapolis, MN! With...

Medscape Education

- PMLiVE

Johnson & Johnson files FDA application for Tremfya in psoriatic arthritis

Approximately 125 million people globally are living with some form of psoriasis

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links